Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccines in chronic liver disease
NCT04775069Phase 4Completed
- Sponsor
- Humanity & Health Medical Group
- Start
- May 2021
- Primary completion
- Sep 2023
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran, coronavac, ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by Humanity & Health Medical Group. Started May 2021; status: completed.
02
Drugs
tozinamerancoronavacChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04775069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775069.